Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events

INTRODUCTION: Anti-PD-1 therapies, pembrolizumab and nivolumab, are currently the standard of care for treatment of patients with metastatic melanoma. Treatment is usually continued until toxicity or disease progression. Though these therapies are well tolerated, some patients discontinue them due t...

Descripción completa

Detalles Bibliográficos
Autores principales: Swami, Umang, Monga, Varun, Bossler, Aaron D., Zakharia, Yousef, Milhem, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683789/
https://www.ncbi.nlm.nih.gov/pubmed/31428149
http://dx.doi.org/10.1155/2019/1856594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683789/
https://www.ncbi.nlm.nih.gov/pubmed/31428149
http://dx.doi.org/10.1155/2019/1856594

Ejemplares similares